A carregar...
A73 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR COMPARED TO ORIGINATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN’S DISEASE
BACKGROUND: Originator infliximab (marketed as Remicade) was the first biological therapy approved in patients with Crohn’s Disease (CD), and has been proven to be effective for the induction and maintenance of remission in patients with moderate-to-severe disease. Due to its recent patent expiry, a...
Na minha lista:
| Publicado no: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6508372/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.073 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|